Lars Wallentin

Author PubWeight™ 3.79^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.	Lancet	2016	3.02
2	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.	Am Heart J	2016	0.78
3	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.	Am Heart J	2015	0.77
4	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.	Am Heart J	2017	0.75
5	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.	Am Heart J	2017	0.75
6	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.	J Am Coll Cardiol	2017	0.75
7	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease.	J Am Coll Cardiol	2017	0.75